BSEInsider Trading / SAST13 Oct 2026 · 13 Oct 2026, 10:28 am
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 12, 2026 for V C Nannapaneni
Natco Pharma Ltd · 524816
✦ AI SummaryPromoter Reclassif.
Natco Pharma Ltd has made a disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, indicating a potential change in control or significant stake acquisition.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern5/10
Regulatory Risk6/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Natco Pharma Ltd - 524816 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.